Anthem Biosciences Q2 FY27: revenue up 8.0% to ₹594 Cr, net profit up 21.9% to ₹212 Cr
Results · Finvezto · 4 Nov 2026 · Anthem Biosciences (ANTHEM)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 594 | - | +8.0% |
| Operating profit | 272 | - | +24.6% |
| Net profit | 212 | - | +21.9% |
| Operating margin | 45.7% | - | +6.1 pp |
| Net margin | 35.6% | - | +4.1 pp |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- For Q2 FY27, consolidated revenue from operations rose to INR594 crores, with CRDMO at INR509 crores and Specialty Ingredients at INR85 crores, EBITDA of INR330 crores at 50.6% margin, and PAT of INR211 crores. Earnings call
- H1 FY27 revenue was INR1,012 crores with EBITDA of INR506 crores at 46.2% margin and PAT of INR331 crores at 30.2%, and net cash stood at INR1,534 crores as of September 30, 2026. Earnings call
- Management said underlying demand continues to remain strong, and better RFP and RFQ inflows were seen in the last quarter, though the revival in biotech funding has been a mixed bag amid geopolitical uncertainty. Earnings call
What to watch
- Management on capex: It is intact. Our capex guidance for the next two years, largely on account of Unit four, which is a large-scale facility which we are building across 30 acres, is close to about INR1,200 crores, and we continue to have that guidance.
- Management on revenue_growth: Doubledigit growth definitely we will try to deliver.
Links
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.